Evidence map›Paper›PMID 24856585›Full record

ArticleCancer cell2014

Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma.

Andrew D Rhim, Paul E Oberstein, Dafydd H Thomas, Emily T Mirek, Carmine F Palermo, Stephen A Sastra, Erin N Dekleva, Tyler Saunders, Claudia P Becerra, Ian W Tattersall and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1,329 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,329citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1,329 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

1,269 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Andrew D RhimDivision of Gastroenterology, Department of Internal Medicine and Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Gastroenterology Division, Department of Medicine and Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Paul E ObersteinDivision of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY 10032, USA.
Dafydd H ThomasDivision of Digestive and Liver Diseases in the Department of Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY 10032, USA; Department of Pathology and Cell Biology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY 10032, USA.
Emily T MirekGastroenterology Division, Department of Medicine and Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Carmine F PalermoDivision of Digestive and Liver Diseases in the Department of Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY 10032, USA; Department of Pathology and Cell Biology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY 10032, USA.
Stephen A SastraDivision of Digestive and Liver Diseases in the Department of Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY 10032, USA; Department of Pathology and Cell Biology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY 10032, USA.
Erin N DeklevaGastroenterology Division, Department of Medicine and Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Tyler SaundersSol Goldman Pancreatic Cancer Research Center and Department of Pathology, Johns Hopkins University, Baltimore, MD 21287, USA.
Claudia P BecerraDepartment of Pathology and Cell Biology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY 10032, USA.
Ian W TattersallDepartment of Pathology and Cell Biology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY 10032, USA.
C Benedikt WestphalenDivision of Digestive and Liver Diseases in the Department of Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY 10032, USA.
Jan KitajewskiDepartment of Pathology and Cell Biology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY 10032, USA.
Maite G Fernandez-BarrenaSchulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.
Martin E Fernandez-ZapicoSchulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.
Christine Iacobuzio-DonahueSol Goldman Pancreatic Cancer Research Center and Department of Pathology, Johns Hopkins University, Baltimore, MD 21287, USA.
Kenneth P OliveDivision of Digestive and Liver Diseases in the Department of Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY 10032, USA; Department of Pathology and Cell Biology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY 10032, USA. Electronic address: kenolive@columbia.edu.
Ben Z StangerGastroenterology Division, Department of Medicine and Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: bstanger@exchange.upenn.edu.

Funding

UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI SHELLEY L BERGER · 1985 to 2026
$222.3M
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3M
Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Parisa Tehranifar · 1985 to 2026
$115.3M
TRANSGENIC AND CHIMERIC MOUSE COREP30DK050306 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI Ken Hashigiwa Cadwell · 1997 to 2026
$32.5M
University of Michigan Center for Gastrointestinal ResearchP30DK034933 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI OWYANG, CHUNG · 1986 to 2021
$22.5M
PILOT AND FEASIBILTY PROGRAMP30DK084567 · NIDDK · MAYO CLINIC ROCHESTER · PI GREGORY J. GORES · 2009 to 2026
$22.2M
CELL, MOLECULAR AND DEVELOPMENTAL BIOLOGY OF CANCERT32CA009503 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI GAUTIER, JEAN · 1985 to 2016
$6.8M
Notch in Angiogenesis and Vascular BiologyR01HL112626 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI Jan K. Kitajewski · 2012 to 2026
$6.3M
Mechanisms of bile duct reprogrammingR01DK083355 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI GROMPE, MARKUS, STANGER, BEN Z · 2009 to 2020
$4.3M
Immunobiology and immunotherapy of pancreatic cancerR01CA169123 · NCI · UNIVERSITY OF PENNSYLVANIA · PI STANGER, BEN Z, VONDERHEIDE, ROBERT H · 2012 to 2016
$3.1M
Mechanism of Pancreatic CarcinogenesisR01CA136526 · NCI · MAYO CLINIC ROCHESTER · PI FERNANDEZ-ZAPICO, MARTIN ERNESTO · 2009 to 2019
$3.0M
AN IN VIVO APPROACH TO CELL-BASED THERAPY FOR TYPE I DIABETESDP2DK083111 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI STANGER, BEN Z · 2008 to 2010
$2.4M
NCI NIH HHS CA046952NCI NIH HHS CA136526NCI NIH HHS CA157980NCI NIH HHS CA169123NCI NIH HHS CA177857NCI NIH HHS P30 CA013696NCI NIH HHS P30CA013696NCI NIH HHS P30 CA015083NCI NIH HHS P30 CA016520NCI NIH HHS R01 CA136526NCI NIH HHS R01 CA157980NCI NIH HHS R01 CA169123NCI NIH HHS R01 CA177857NCI NIH HHS T32 CA009503NCI NIH HHS T32CA009503NCRR NIH HHS S10 RR025482NCRR NIH HHS S10 RR025686NCRR NIH HHS S10RR025686NHLBI NIH HHS R01 HL112626NIDDK NIH HHS DK034933NIDDK NIH HHS DK083111NIDDK NIH HHS DK083355NIDDK NIH HHS DK088945NIDDK NIH HHS DP2 DK083111NIDDK NIH HHS K08 DK088945NIDDK NIH HHS P30 DK034933NIDDK NIH HHS P30 DK050306NIDDK NIH HHS P30DK050306NIDDK NIH HHS P30 DK084567NIDDK NIH HHS R01 DK083355
6 · The paper itself

Abstract

Sonic hedgehog (Shh), a soluble ligand overexpressed by neoplastic cells in pancreatic ductal adenocarcinoma (PDAC), drives formation of a fibroblast-rich desmoplastic stroma. To better understand its role in malignant progression, we deleted Shh in a well-defined mouse model of PDAC. As predicted, Shh-deficient tumors had reduced stromal content. Surprisingly, such tumors were more aggressive and exhibited undifferentiated histology, increased vascularity, and heightened proliferation--features that were fully recapitulated in control mice treated with a Smoothened inhibitor. Furthermore, administration of VEGFR blocking antibody selectively improved survival of Shh-deficient tumors, indicating that Hedgehog-driven stroma suppresses tumor growth in part by restraining tumor angiogenesis. Together, these data demonstrate that some components of the tumor stroma can act to restrain tumor growth.

Indexed as

AnimalsAntibodies, MonoclonalCarcinoma, Pancreatic DuctalCell Line, TumorDisease Models, AnimalDisease ProgressionGene Knockdown TechniquesHedgehog ProteinsHumansImmunoglobulin GMiceMice, TransgenicPancreatic NeoplasmsRandom AllocationReceptors, Vascular Endothelial Growth FactorSignal TransductionAntibodies, MonoclonalDC101 monoclonal antibodyHedgehog ProteinsImmunoglobulin GReceptors, Vascular Endothelial Growth Factor

Identifiers

PMID24856585
PMCPMC4096698

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.